Amarin (AMRN) Sees Downside Ahead of NCE Decision
Tweet Send to a FriendGet Alerts AMRN Hot Sheet
Down)
Trade AMRN Now!
Amarin Corporation plc (Nasdaq: AMRN) is under pressure mid-day ahead of the all-important decision on NCE status for Vascepa.
A decision is expected this week, although nothing has been released at this point. Nonetheless, traders appear to have an itchy trigger finger.
Shares of AMRN last traded at $12.31, down 2.7 percent.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
A decision is expected this week, although nothing has been released at this point. Nonetheless, traders appear to have an itchy trigger finger.
Shares of AMRN last traded at $12.31, down 2.7 percent.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Amarin's (AMRN) Vascepa Not in FDA Orange Book for April
- Qihoo 360 (QIHU) Hits 52-Week High Into Q1 Results
- Tableau Software (DATA) IPO now indicated $42-$44
Create E-mail Alert Related Categories
FDA, Trader Talk
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
